Hypofractionation and radiotherapy: "L'éternel retour";Hypofractionnement en radiothérapie: L'éternel retour

Cancer/Radiotherapie

Volumn 17, Issue 5-6, 2013, Pages 355-362

  Cosset, J M ^a,b   Mornex, F ^c,d   Eschwege F ^e  

^a INSTITUT CURIE   (France)

^b Hospital Prive des Peupliers   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^e Centre Antoine Béclère   (France)

Author keywords

Fractionation; Prostate cancer; Radiotherapy; Time factors

Indexed keywords

CANCER RADIOTHERAPY; HYPOFRACTIONATION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SHORT SURVEY;

CANCER DE PROSTATE; FACTEURS TEMPS; FRACTIONATION; FRACTIONNEMENT; PROSTATE CANCER; RADIOTHÉRAPIE; RADIOTHERAPY; TIME FACTORS;

DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84884350719     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2013.06.027     Document Type: Short Survey

References (61)

1. Willers H., Beck-Bornholdt H.P. Origins of radiotherapy and radiobiology: separation of the influence of dose per fraction and overall treatment time on normal tissue damage by Reisner and Miescher in the 1930s. Radiother Oncol 1996, 38:171-173.
2. Winston B.M., Ellis F., Hall E.J. The Oxford NSD calculator for clinical use. Clin Radiol 1969, 20:8-11.
3. Thames H.D. Early fractionation methods and the origins of the NSD concept. Acta Oncol 1988, 27:89-103.
4. Kirk J., Gray W.M., Watson E.R. Cumulative radiation effect. I. Fractionated treatment regimes. Clin Radiol 1971, 22:145-155.
5. Orton C.G., Ellis F. A simplification in the use of the NSD concept in practical radiotherapy. Br J Radiol 1973, 46:529-537.
6. Gallez-Marchal D., Fayolle M., Henry-Amar M., Le Bourgeois J.P., Rougier P., Cosset J.M. Radiation injuries of the gastrointestinal tract in Hodgkin's disease: the role of exploratory laparotomy and fractionation. A study of 19cases observed in a series of 134patients treated at the Institut Gustave-Roussy from 1972to 1982. Radiother Oncol 1984, 2:93-99.
7. Cosset J.M., Henry-Amar M., Girinski T., Malaise E., Dupouy N., Dutreix J. Late toxicity of radiotherapy in Hodgkin's disease. The role of fraction size. Acta Oncol 1988, 27:123-129.
8. Cosset J.M., Girinsky T., Malaise E., Chaillet M.P., Dutreix J. Clinical basis for TBI fractionation. Radiother Oncol 1990, 18Suppl 1:60-67.
9. Dubray B., Henry-Amar M., Meerwaldt J.H., Noordijk E.M., Dixon D.O., Cosset J.M., et al. Radiation-induced lung damage after thoracic irradiation for Hodgkin's disease: the role of fractionation. Radiother Oncol 1995, 36:211-217.
10. Dolinsky C., Glatstein E. Some cases of severe normal tissue toxicity can be anticipated with ablated fractionated radiation with appropriate long-term follow-up. Semin Radiat Oncol 2008, 18:229-233.
11. Fertil B., Malaise E.P. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101published survival curves. Int J Radiat Oncol Biol Phys 1985, 11:1699-1707.
12. Joiner M.C., Lambin P., Malaise E.P., Robson T., Arrand J.E., Skov K.A., et al. Hypersensitivity to very-low single radiation doses: its relationship to the adaptive response and induced radioresistance. Mutat Res 1996, 358:171-183.
13. Short S.C., Kelly J., Mayes C.R., Woodcock M., Joiner M.C. Low-dose hypersensitivity after fractionated low-dose irradiation in vitro. Int J Radiat Biol 2001, 77:655-664.
14. Dionet C., Tchirkov A., Alard J.P., Arnold J., Dhermain J., Rapp M., et al. Effects of low-dose neutrons applied at reduced dose rate on human melanoma cells. Radiat Res 2000, 154:406-411.
15. Böhrnsen G., Weber K.J., Scholz M. Measurement of biological effects of high-energy carbon ions at low doses using a semi-automated cell detection system. Int J Radiat Biol 2002, 78:259-266.
16. Hamilton C.S., Denham J.W., O'Brien M., Ostwald P., Kron T., Wright S., et al. Underprediction of human skin erythema at low doses per fraction by the linear quadratic model. Radiother Oncol 1996, 40:23-30.
17. Turesson I., Joiner M.C. Clinical evidence of hypersensitivity to low doses in radiotherapy. Radiother Oncol 1996, 40:1-3.
18. Dutreix J., Cosset J.M., Girinsky T. Équivalent biologique des fortes doses utilisées en irradiation peropératoire. Bull Cancer Radiother 1990, 77:125-134.
19. Astrahan M. Some implications of linear-quadratic-linear radiation dose-response with regard to hypofractionation. Med Phys 2008, 35:4161-4172.
20. Ritter M. Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Semin Radiat Oncol 2008, 18:249-256.
21. Fowler J.F., Ritter M.A., Chappell R.J., Brenner D.J. What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys. 2003, 56:1093-1104.
22. Fowler J., King C.R. Don't squeeze hypofractionated schedules into too-short overall times. Int J Radiat Oncol Biol Phys 2009, 75:323-325.
23. Anastasiadis A.G., Stisser B.C., Ghafar M.A., Burchardt M., Buttyan R. Tumor hypoxia and the progression of prostate cancer. Curr Urol Rep 2002, 3:222-228.
24. Yip K., Alonzi R. Carbogen gas and radiotherapy outcomes in prostate cancer. Ther Adv Urol 2013, 5:25-34.
25. Nahum A.E., Movsas B., Horwitz E.M., Stobbe C.C., Chapman J.D. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys 2003, 57:391-401.
26. Duchesne G.M., Peters L.J. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 1999, 44:747-748.
27. Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999, 43:1095-1101.
28. King C.R., Mayo C.S. Is the prostate alpha/beta ratio of 1.5from Brenner & Hall a modeling artifact. Int J Radiat Oncol Biol Phys 2000, 47:536-539.
29. Fowler J., Chappell R., Ritter M. Is α/β for prostate tumors really low?. Int J Radiat Oncol Biol Phys 2001, 50:1021-1031.
30. King C.R., Fowler J.F. A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys 2001, 51:213-214.
31. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002, 52:6-13.
32. Bentzen S.M., Ritter M.A. The alpha/beta ratio for prostate cancer: what is it, really?. Radiother Oncol 2005, 76:1-3.
33. Loblaw D.A., Cheung P. External beam irradiation for localized prostate cancer - the promise of hypofractionation. Can J Urol 2006, 13Suppl 1:62-66.
34. Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?. Clin Oncol (R Coll Radiol) 2007, 19:289-301.
35. Proust-Lima C., Taylor J.M., Sécher S., Sandler H., Kestin L., Pickles T., et al. Confirmation of a low alpha/beta ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys 2011, 79:195-201.
36. Leborgne F., Fowler J., Leborgne J.H., Mezzera J. Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:1200-1207.
37. Kupelian P.A., Thakkar V.V., Khuntia D., Reddy C.A., Klein E.A., Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70Gy at 2.5Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 2005, 63:1463-1468.
38. Kupelian P.A., Willoughby T.R., Reddy C.A., Klein E.A., Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70Gy at 2.5Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007, 68:1424-1430.
39. Martin J.M., Rosewall T., Bayley A., Bristow R., Chung P., Crook J., et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007, 69:1084-1089.
40. Okada T., Tsuji H., Kamada T., Akakura K., Suzuki H., Shimazaki J., et al. Carbon ion radiotherapy in advanced hypofractionated regimens for prostate cancer: from 20to 16fractions. Int J Radiat Oncol Biol Phys 2012, 84:968-972.
41. Fonteyne V., Soete G., Arcangeli S., De Neve W., Rappe B., Storme G., et al. Hypofractionated high-dose radiation therapy for prostate cancer: long-term results of a multi-institutional phase II trial. Int J Radiat Oncol Biol Phys 2012, 84:483-490.
42. Adkison J.B., McHaffie D.R., Bentzen S.M., Patel R.R., Khuntia D., Petereit D.G., et al. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:184-190.
43. Madsen B.L., Hsi R.A., Pham H.T., Fowler J.F., Esagui L., Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007, 67:1099-1105.
44. Tang C.I., Loblaw D.A., Cheung P., Holden L., Morton G., Basran P.S., et al. Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. 35Gy in five fractions, once a week over 29days. Clin Oncol (R Coll Radiol) 2008, 20:729-737.
45. Williams S.G., Taylor J.M., Liu N., Tra Y., Duchesne G.M., Kestin L.L., et al. Use of individual fraction size data from 3756patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 2007, 68:24-33.
46. Kal H.B., Van Gellekom M.P. How low is the alpha/beta ratio for prostate cancer?. Int J Radiat Oncol Biol Phys 2003, 57:1116-1121.
47. Orton C.G. In regard to Nahum et al. (Int J Radiat Oncol Biol Phys 2003;57:391-401): incorporating clinical measurements of hypoxia into tumor control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys 2004, 58:1637.
48. Valdagni R., Italia C., Montanaro P., Lanceni A., Lattuada P., Magnani T., et al. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiother Oncol 2005, 75:74-82.
49. Nickers P., Hermesse J., Deneufbourg J.M., Vanbelle S., Lartigau E. Which á/â ratio and half-time of repair are useful for predicting outcomes in prostate cancer?. Radiother Oncol 2010, 97:462-466.
50. Lennernäs B., Nilsson S., Levitt S. Hypofractionation for radiotherapy of prostate cancer using a low alfa/beta ratio - possible reasons for concerns? An example of five dimensional radiotherapy. Acta Oncol 2011, 50Suppl 1:111-115.
51. Lukka H., Hayter C., Julian J.A., Warde P., Morris W.J., Gospodarowicz M., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005, 23:6132-6138.
52. Yeoh E.E., Botten R.J., Butters J., Di Matteo A.C., Holloway R.H., Fowler J. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 2011, 81:1271-1278.
53. Pollack A., Hanlon A.L., Horwitz E.M., Feigenberg S.J., Konski A.A., Movsas B., et al. Dosimetry and preliminary acute toxicity in the first 100men treated for prostate cancer on a randomized hypofractionation dose escalation trial. IJRO 2006, 64:518-526.
54. Norkus D., Miller A., Kurtinaitis J., Haverkamp U., Popov S., Prott F.J., et al. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlenther Onkol 2009, 185:715-721.
55. Arcangeli S., Strigari L., Gomellini S., Saracino B., Petrongari M.G., Pinnarò P., et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. IJRO 2012, 84:1172-1178.
56. Dearnaley D., Syndikus I., Sumo G., Bidmead M., Bloomfield D., Clark C., et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012, 13:43-54.
57. Ghilezan M. Role of high dose rate brachytherapy in the treatment of prostate cancer. Cancer Radiother 2012, 16:418-422.
58. Crook J. The role of brachytherapy in the definitive management of prostate cancer. Cancer Radiother 2011, 15:230-237.
59. Chen L.N., Suy S., Uhm S., Oermann E.K., Ju A.W., Chen V., et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol 2013, 8:58.
60. ®) for prostate cancer treatment. BJU Int 2013, 111:761-766.
61. Dubray B.M., Thames H.D. Chronic radiation damage in the rat rectum: an analysis of the influences of fractionation, time and volume. Radiother Oncol 1994, 33:41-47.